Siren L.L.C. Decreases Stock Holdings in NewAmsterdam Pharma Company N.V. $NAMS

Key Points

• Siren L.L.C. reduced its stake in NewAmsterdam Pharma by 8.8% in the first quarter, maintaining approximately 2.3% of its portfolio in the company.
• Several large investors, including Wellington Management Group LLP and Aberdeen Group plc, significantly increased their stakes in NewAmsterdam Pharma during the same period.
• Analysts have assigned a consensus rating of "Moderate Buy" for NewAmsterdam Pharma, with an average target price of $41.55, while some firms set price targets as high as $45.00.

Siren L.L.C. lowered its position in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report) by 8.8% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,912,030 shares of the company's stock after selling 183,608 shares during the period. NewAmsterdam Pharma makes up approximately 2.3% of Siren L.L.C.'s portfolio, making the stock its 13th largest position. Siren L.L.C. owned about 1.74% of NewAmsterdam Pharma worth $39,139,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of NewAmsterdam Pharma by 19.4% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,675 shares of the company's stock worth $80,000 after buying an additional 596 shares during the last quarter. GF Fund Management CO. LTD. acquired a new stake in shares of NewAmsterdam Pharma during the 4th quarter worth approximately $50,000. China Universal Asset Management Co. Ltd. increased its holdings in shares of NewAmsterdam Pharma by 12.5% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 22,028 shares of the company's stock worth $451,000 after buying an additional 2,439 shares during the last quarter. HB Wealth Management LLC increased its holdings in shares of NewAmsterdam Pharma by 28.9% during the 1st quarter. HB Wealth Management LLC now owns 11,247 shares of the company's stock worth $230,000 after buying an additional 2,519 shares during the last quarter. Finally, Alps Advisors Inc. increased its holdings in shares of NewAmsterdam Pharma by 4.4% during the 1st quarter. Alps Advisors Inc. now owns 77,961 shares of the company's stock worth $1,596,000 after buying an additional 3,252 shares during the last quarter. Institutional investors and hedge funds own 89.89% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. Royal Bank Of Canada raised their price target on shares of NewAmsterdam Pharma from $38.00 to $39.00 and gave the stock an "outperform" rating in a report on Thursday, August 7th. Wall Street Zen upgraded shares of NewAmsterdam Pharma from a "sell" rating to a "hold" rating in a report on Saturday, July 5th. Needham & Company LLC reiterated a "buy" rating and issued a $40.00 target price on shares of NewAmsterdam Pharma in a report on Thursday, June 12th. Wells Fargo & Company began coverage on shares of NewAmsterdam Pharma in a report on Monday, August 25th. They issued an "overweight" rating and a $45.00 target price for the company. Finally, Citigroup began coverage on shares of NewAmsterdam Pharma in a report on Tuesday, June 17th. They issued a "buy" rating and a $42.00 target price for the company. Nine research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat, NewAmsterdam Pharma has a consensus rating of "Moderate Buy" and a consensus price target of $41.55.

NewAmsterdam Pharma Stock Performance

Shares of NASDAQ:NAMS traded up $0.10 during trading on Friday, hitting $24.05. The company's stock had a trading volume of 850,991 shares, compared to its average volume of 826,589. The business has a 50 day moving average price of $22.29 and a two-hundred day moving average price of $20.38. The company has a market capitalization of $2.71 billion, a PE ratio of -14.85 and a beta of -0.01. NewAmsterdam Pharma Company N.V. has a fifty-two week low of $14.06 and a fifty-two week high of $27.29.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.52) by $0.37. The business had revenue of $19.15 million during the quarter, compared to the consensus estimate of $1.44 million. NewAmsterdam Pharma had a negative net margin of 259.07% and a negative return on equity of 27.27%. As a group, equities analysts expect that NewAmsterdam Pharma Company N.V. will post -1.75 earnings per share for the current fiscal year.

Insider Buying and Selling at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, insider Johannes Jacob Piete Kastelein sold 50,000 shares of the business's stock in a transaction on Thursday, August 21st. The shares were sold at an average price of $24.29, for a total value of $1,214,500.00. Following the completion of the transaction, the insider owned 119,302 shares in the company, valued at $2,897,845.58. The trade was a 29.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director James N. Topper purchased 8,584 shares of the company's stock in a transaction on Monday, June 16th. The stock was acquired at an average price of $19.50 per share, with a total value of $167,388.00. Following the purchase, the director owned 3,022,153 shares of the company's stock, valued at approximately $58,931,983.50. This represents a 0.28% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders have acquired 12,835 shares of company stock worth $248,134 and have sold 256,881 shares worth $5,445,954. Corporate insiders own 20.84% of the company's stock.

NewAmsterdam Pharma Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.